Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Novel and potent cyclic cyanamide-based cathepsin K inhibitors.

Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Tavares FX, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1815-9.

PMID:
15780613
2.

Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.

Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1735-9. Epub 2006 Jan 11.

PMID:
16376075
3.

Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.

Altmann E, Cowan-Jacob SW, Missbach M.

J Med Chem. 2004 Nov 18;47(24):5833-6.

PMID:
15537340
4.

Acyclic cyanamide-based inhibitors of cathepsin K.

Barrett DG, Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Payne JA, Shewchuk LM, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43.

PMID:
15896958
5.

Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.

Thompson SK, Smith WW, Zhao B, Halbert SM, Tomaszek TA, Tew DG, Levy MA, Janson CA, DAlessio KJ, McQueney MS, Kurdyla J, Jones CS, DesJarlais RL, Abdel-Meguid SS, Veber DF.

J Med Chem. 1998 Oct 8;41(21):3923-7.

PMID:
9767629
6.

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH Jr, Wright LL, Zhou HQ.

J Med Chem. 2004 Jan 29;47(3):588-99.

PMID:
14736240
7.

Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.

Marquis RW, Yamashita DS, Ru Y, LoCastro SM, Oh HJ, Erhard KF, DesJarlais RL, Head MS, Smith WW, Zhao B, Janson CA, Abdel-Meguid SS, Tomaszek TA, Levy MA, Veber DF.

J Med Chem. 1998 Sep 10;41(19):3563-7. No abstract available.

PMID:
9733481
8.

Identification of a potent and selective non-basic cathepsin K inhibitor.

Li CS, Deschenes D, Desmarais S, Falgueyret JP, Gauthier JY, Kimmel DB, Léger S, Massé F, McGrath ME, McKay DJ, Percival MD, Riendeau D, Rodan SB, Thérien M, Truong VL, Wesolowski G, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):1985-9. Epub 2006 Jan 18.

PMID:
16413777
9.

Dioxo-triazines as a novel series of cathepsin K inhibitors.

Rankovic Z, Cai J, Fradera X, Dempster M, Mistry A, Mitchell A, Long C, Hamilton E, King A, Boucharens S, Jamieson C, Gillespie J, Cumming I, Uitdehaag J, van Zeeland M.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1488-90. doi: 10.1016/j.bmcl.2010.01.116. Epub 2010 Jan 25.

PMID:
20153187
10.

4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors.

Shinozuka T, Shimada K, Matsui S, Yamane T, Ama M, Fukuda T, Taki M, Naito S.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1502-5. Epub 2005 Dec 27.

PMID:
16380250
11.

Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.

Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):22-7. Epub 2006 Nov 17.

PMID:
17157021
12.

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.

Barrett DG, Boncek VM, Catalano JG, Deaton DN, Hassell AM, Jurgensen CH, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Ray JA, Samano V, Shewchuk LM, Tavares FX, Wells-Knecht KJ, Willard DH Jr, Wright LL, Zhou HQ.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3540-6.

PMID:
15982880
13.

Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.

Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Shewchuk LM, Wells-Knecht KJ, Willard DH Jr, Wright LL.

Bioorg Med Chem Lett. 2004 Oct 4;14(19):4897-902.

PMID:
15341947
14.

Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.

Alper PB, Liu H, Chatterjee AK, Nguyen KT, Tully DC, Tumanut C, Li J, Harris JL, Tuntland T, Chang J, Gordon P, Hollenbeck T, Karanewsky DS.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1486-90. Epub 2006 Jan 18.

PMID:
16412634
15.

3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.

Setti EL, Davis D, Janc JW, Jeffery DA, Cheung H, Yu W.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1529-34.

PMID:
15713422
16.

Solid-phase synthesis of a combinatorial array of 1,3-bis(acylamino)-2-butanones, inhibitors of the cysteine proteases cathepsins K and L.

Yamashita DS, Dong X, Oh HJ, Brook CS, Tomaszek TA, Szewczuk L, Tew DG, Veber DF.

J Comb Chem. 1999 May-Jun;1(3):207-15.

PMID:
10746010
17.
18.

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.

Barrett DG, Catalano JG, Deaton DN, Long ST, Miller LR, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.

Bioorg Med Chem Lett. 2004 May 17;14(10):2543-6.

PMID:
15109647
19.

Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.

Yamashita DS, Xie R, Lin H, Wang B, Shi SD, Quinn CJ, Hemling ME, Hissong C, Tomaszek TA, Veber DF.

J Pept Res. 2004 Mar;63(3):265-9.

PMID:
15049838
20.

A structural screening approach to ketoamide-based inhibitors of cathepsin K.

Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Wells-Knecht KJ, Wright LL.

Bioorg Med Chem Lett. 2005 May 2;15(9):2209-13.

PMID:
15837295

Supplemental Content

Support Center